{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:48:53Z","timestamp":1761896933881,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12185-018-02571-0","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T07:16:33Z","timestamp":1543821393000},"page":"162-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Andou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiwa","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"issue":"19","key":"2571_CR1","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"8","key":"2571_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"16","key":"2571_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"2571_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"key":"2571_CR5","first-page":"243","volume":"8","author":"GD Miller","year":"2014","unstructured":"Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph(+)ALL\u2014role of ponatinib. Biologics. 2014;8:243\u201354.","journal-title":"Biologics"},{"issue":"3","key":"2571_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12185-017-2238-9","volume":"106","author":"A Tojo","year":"2017","unstructured":"Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, et al. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study. Int J Hematol. 2017;106(3):385\u201397.","journal-title":"Int J Hematol"},{"issue":"15","key":"2571_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547\u201355.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2571_CR8","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650\u20136.","journal-title":"Cancer"},{"issue":"6","key":"2571_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"1","key":"2571_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/bmt.2015.217","volume":"51","author":"S Nishiwaki","year":"2016","unstructured":"Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph + ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transpl. 2016;51(1):43\u201350.","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2571_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","volume":"17","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):897\u2013901.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2571_CR12","doi-asserted-by":"publisher","first-page":"bcr2014203894","DOI":"10.1136\/bcr-2014-203894","volume":"2014","author":"Z Robinson","year":"2014","unstructured":"Robinson S, Levy Y, Maisel C, Tong AW. Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph+ pre-B acute lymphoblastic leukaemia. BMJ Case Rep. 2014;2014:bcr2014203894.","journal-title":"BMJ Case Rep"},{"issue":"8","key":"2571_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.clml.2016.04.017","volume":"16","author":"Z DeFilipp","year":"2016","unstructured":"DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016;16(8):466\u201371.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2571_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood"},{"key":"2571_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84\u201391.","journal-title":"Leuk Res"},{"issue":"4","key":"2571_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/hon.2517","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A. Upfront low-dose ponatinib (15\u00a0mg\/day) for multi-TKI resistant chronic myeloid leukemia. Hematol Oncol. 2018;36(4):718\u201320.","journal-title":"Hematol Oncol"},{"issue":"5","key":"2571_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","volume":"38","author":"A Iurlo","year":"2018","unstructured":"Iurlo A, Cattaneo D, Orofino N, Bucelli C, Molica M, Breccia M. Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option. Clin Drug Investig. 2018;38(5):475\u20136.","journal-title":"Clin Drug Investig"},{"key":"2571_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.leukres.2017.11.012","volume":"64","author":"M Abumiya","year":"2018","unstructured":"Abumiya M, Miura M, Takahashi N. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients. Leuk Res. 2018;64:42\u20135.","journal-title":"Leuk Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-02571-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-02571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-02571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:24:48Z","timestamp":1575314688000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-02571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-02571-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"31 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}